JP2021512151A5 - - Google Patents
Info
- Publication number
- JP2021512151A5 JP2021512151A5 JP2020561589A JP2020561589A JP2021512151A5 JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5 JP 2020561589 A JP2020561589 A JP 2020561589A JP 2020561589 A JP2020561589 A JP 2020561589A JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024047473A JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
| JP2026049832A JP2026098127A (ja) | 2018-01-23 | 2026-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620545P | 2018-01-23 | 2018-01-23 | |
| US62/620,545 | 2018-01-23 | ||
| PCT/US2019/014748 WO2019147670A1 (en) | 2018-01-23 | 2019-01-23 | B7-h4 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Division JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512151A JP2021512151A (ja) | 2021-05-13 |
| JP2021512151A5 true JP2021512151A5 (enExample) | 2022-01-31 |
Family
ID=67396234
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561589A Pending JP2021512151A (ja) | 2018-01-23 | 2019-01-23 | Ｂ７−ｈ４抗体およびその使用方法 |
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
| JP2026049832A Pending JP2026098127A (ja) | 2018-01-23 | 2026-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
| JP2026049832A Pending JP2026098127A (ja) | 2018-01-23 | 2026-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12286478B2 (enExample) |
| EP (1) | EP3743447B1 (enExample) |
| JP (3) | JP2021512151A (enExample) |
| KR (2) | KR20260086818A (enExample) |
| CN (2) | CN112566934B (enExample) |
| AU (1) | AU2019211326B2 (enExample) |
| BR (1) | BR112020014929A2 (enExample) |
| CA (1) | CA3089469A1 (enExample) |
| DK (1) | DK3743447T3 (enExample) |
| ES (1) | ES2980171T3 (enExample) |
| WO (1) | WO2019147670A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| AU2020242794B2 (en) * | 2019-03-21 | 2024-02-01 | Beijing Kanova Biopharmaceutical Co., Ltd. | Anti-B7S1 polypeptides and their use |
| JP7726534B2 (ja) * | 2020-06-30 | 2025-08-20 | 諾納生物（蘇州）有限公司 | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| AU2024397390A1 (en) * | 2023-12-11 | 2026-05-28 | Ligachem Biosciences, Inc. | B7-h4 antibody-drug conjugates and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ATE413466T1 (de) | 1998-09-02 | 2008-11-15 | Diadexus Inc | Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007056539A2 (en) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| WO2007065167A1 (en) | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| EP2586458B1 (en) | 2006-12-27 | 2016-08-24 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| AR069747A1 (es) * | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| EP2473523A2 (en) | 2009-08-31 | 2012-07-11 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| LT2897939T (lt) | 2012-09-21 | 2017-05-10 | Sanofi | Benzimidazolo karboksirūgšties amido dariniai metabolinių arba širdies ir kraujagyslių ligų gydymui |
| AU2013361275B2 (en) * | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| MX2015010777A (es) | 2013-03-14 | 2016-04-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-b7-h4. |
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| US10626176B2 (en) * | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
-
2019
- 2019-01-23 CN CN201980021260.8A patent/CN112566934B/zh active Active
- 2019-01-23 KR KR1020267016295A patent/KR20260086818A/ko active Pending
- 2019-01-23 EP EP19743902.9A patent/EP3743447B1/en active Active
- 2019-01-23 CA CA3089469A patent/CA3089469A1/en active Pending
- 2019-01-23 CN CN202411212034.7A patent/CN119097699A/zh active Pending
- 2019-01-23 DK DK19743902.9T patent/DK3743447T3/da active
- 2019-01-23 KR KR1020207024024A patent/KR20200112913A/ko not_active Ceased
- 2019-01-23 JP JP2020561589A patent/JP2021512151A/ja active Pending
- 2019-01-23 US US16/964,133 patent/US12286478B2/en active Active
- 2019-01-23 ES ES19743902T patent/ES2980171T3/es active Active
- 2019-01-23 WO PCT/US2019/014748 patent/WO2019147670A1/en not_active Ceased
- 2019-01-23 BR BR112020014929-2A patent/BR112020014929A2/pt unknown
- 2019-01-23 AU AU2019211326A patent/AU2019211326B2/en active Active
-
2024
- 2024-03-25 JP JP2024047473A patent/JP2024075721A/ja active Pending
-
2026
- 2026-03-25 JP JP2026049832A patent/JP2026098127A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| CN112739379B (zh) | 包含OX40抗原结合位点的Fc结合片段 | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2022512653A5 (enExample) | ||
| JP2021531754A5 (enExample) | ||
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| HRP20230528T1 (hr) | Bispecifične molekule t stanica aktivirane proteazom | |
| JP2020501531A5 (enExample) | ||
| JP2022512043A5 (enExample) | ||
| US11993655B2 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2019524693A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| KR20200092301A (ko) | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 | |
| CN112111012B (zh) | 共价多特异性抗体 | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| JP2023511898A5 (enExample) | ||
| CA3155293A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| JP2016529213A5 (enExample) | ||
| JP2023504733A5 (enExample) | ||
| JP7813704B2 (ja) | 抗ｂｃｍａ／抗４－１ｂｂ二重特異性抗体及びその用途 | |
| JP2018525347A (ja) | 癌免疫療法に使用するための二重特異性抗体 | |
| CN117480178A (zh) | 嵌合FC-α受体及其用途 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP2024542164A5 (enExample) |